Epimède SA
5
12M
4
2
0.20
1
- Areas of investment
Summary
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Epimu00e8de SA, startups are often financed by Vesalius Biocapital Partners, Sambrinvest, SFPI-FPIM. The meaningful sponsors for the fund in investment in the same round are SFPI-FPIM, S.R.I.W., Vesalius Biocapital Partners.
The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Diagenode, Endo Tools Therapeutics, Ncardia. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biotechnology.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 5 - 10 millions dollars. The high activity for fund was in 2016.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 2
- Exits
- 1
- Follow on index
- 0.20
- Investments by industry
- Biotechnology (3)
- Medical (3)
- Health Care (3)
- Medical Device (2)
- Pharmaceutical (2) Show 3 more
- Investments by region
-
- Belgium (4)
- Netherlands (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 39M
- Group Appearance index
- 1.00
- Avg. company exit year
- 18
- Avg. multiplicator
- 17.97
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Imcyse | 17 Feb 2021 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 25M | Liège, Liège, Belgium |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.